Is Retatrutide FDA Approved? Current Status and Regulatory Steps

Current status

Retatrutide is not FDA-approved. FDA also states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound, sell or maintain a product waitlist for retatrutide. A clinic listing or research-only label does not establish approved clinical access.

What Lilly has announced

In its July 23, 2026 announcement, Lilly said it plans to submit a Biologics License Application in the first quarter of 2027. That statement should be attributed to the sponsor. It is not a promise of approval, a confirmed FDA decision date or a settled commercial launch date.

Keep the milestones separate

Completion of a trial, announcement of results, publication, submission of an application, acceptance for review and an approval decision are different events. Even favorable trial results do not settle a future indication, warnings, prescribing information, coverage or price. The trial record must also be identified accurately: TRIUMPH-4 concerns obesity and knee osteoarthritis, not a sleep-apnea trial.

Research participation is not retail availability

ClinicalTrials.gov describes studies, their eligibility criteria and recruitment status. A listing does not guarantee a place or an available access program. General rules for investigational access should not be presented as proof that a specific retatrutide route is currently available. This page reports regulatory research rather than offering a treatment pathway.

Sources

• FDA: unapproved GLP-1 drugs
• Phase 2 obesity trial, NEJM (2023)
• Phase 2 study record, NCT04881760
• Lilly, July 23, 2026